AU
UK
CA
NZ
IND
US
Biopharmaceutical firmNeumora Therapeutics (NASDAQ: NMRA)received a ‘buy’ rating from brokers shortly after its recent listing on the stock market. The stock debuted on the market last month and its price has declined by 28.5% since then.
Broker BofA increased its price target onEli Lilly and Company (NYSE: LLY), a pharmaceutical firm with its key areas of focus being neuroscience, cancer, and immunology. Eli Lilly’s market cap stood at over US$500 billion on Friday
Brokerage RBC initiated its coverage onJohnson & Johnson (NYSE: JNJ), giving the stock an ‘outperform’ rating. The broker et its price target at US$178, an upside potential of over 13% over Thursday’s closing price.
Broker UBS raised its rating onFlour Corp. (NYSE: FLR), to ‘buy’ from ‘neutral’. UBS elevated its price target on the construction firm by US$12 to US$47, which marks an upside potential of 36% over FLR’s closing price on Wednesday.
DrugmakerStructure Therapeutics (NASDAQ: GPCR) saw its share price rising on October 3, 2023, after broker BMO raised its price target on the company. BMO Capital Markets raised its price target on GPCR from US$40 to US$83, leading the stock price to rise by 1.6% …
REIT firmDigitalBridge (NYSE: DBRG)received a rating upgrade from broker J.P. Morgan before market open on September 28, 2023.
BTIG upgraded its price target on REIT firm Hudson Pacific to US$11, the highest price target among all brokers as per EODHD/Others data. The new price target reflects an upside potential of 63.2% over the stock’s closing price on Tuesday.
Brokers raise their price targets onFedEx Corporation (NYSE: FDX), leading to a 2.63% surge in the company’ share price. The stock price reached US$267.97 on September 25, 2023, as Daiwa Capital, Loop Capital and others increase their price target on the FDX.
Medical equipment manufacturerBoston Scientific Corporation (NYSE: BSX)received a price target upgrade from brokers as it projects sales growth of 8% to 10% for 2024 to 2026.
Brokerage Mizuho revised its rating on food distribution companyDoorDash (NYSE: DASH)from ‘neutral’ to ‘buy’. The broker also upped its price target on DoorDash to US$105 from US$90. Mizuho’s upgraded price target represents an upside potential of 29.76% over DASH’s closing price on Monday.
Please wait processing your request...